Daiichi and AstraZeneca hail promising breast cancer treatment results

(marketscreener.com) Daiichi Sankyo Co Ltd on Friday said updated results from a phase 1 trial showed datopotamab deruxtecan continued to show promising responses in patients with breast cancer.The companies said that datopotamab deruxtecan in combination with Imfinzi demonstrated an overall response rate of 74% in patients with previously untreated, unresectable,...https://www.marketscreener.com/quote/stock/DAIICHI-SANKYO-CO-LTD-6498062/news/Daiichi-and-AstraZeneca-hail-promising-breast-cancer-treatment-results-42515338/?utm_medium=RSS&utm_content=20221209